Voyager Therapeutics Up 9%; Restructures Relationship with Sanofi Genzyme
June 17 2019 - 1:17PM
Dow Jones News
By Michael Dabaie
Voyager Therapeutics Inc. (VYGR) shares were up 9% to $26.52 in
midday trading Monday.
The clinical-stage gene therapy company said earlier it
restructured its gene therapy relationship with Sanofi Genzyme.
Voyager said it is gaining world-wide rights to the VY-HTT01
Huntington's disease program and ex-U.S. rights to the VY-FXN01
Friedreich's ataxia program. Voyager is, in turn, transferring the
ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences Inc. (NBIX)
under the terms of a collaboration agreement.
Neurocrine shares were up 2.3% to $85.82.
To focus resources on the now wholly-owned Huntington's disease
program, Voyager said it would seek a partner to advance its
preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager
said it no longer expects to file an investigational new drug
application with the U.S. Food and Drug Administration for its
VY-SOD102 in 2019.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 17, 2019 13:02 ET (17:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Apr 2023 to Apr 2024